Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00115661 · ClinicalTrials.gov registry record · Phase 2
Use of Rosiglitazone in the Treatment of Endometriosis
A Phase 2 study, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- Terminated
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00115661 is a Phase 2 study that was terminated before completion, run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The registered enrollment target is 25 participants.
The verdict
NCT00115661, a Phase 2 study, was terminated before completion, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to perform a pilot study on the efficacy of rosiglitazone in reducing pelvic pain in early stage endometriosis patients.
Interventions
- DRUG Rosiglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2005-07 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)305 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00115661
The ClinicalTrials.gov registry entry for NCT00115661 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rosiglitazone is the first listed.
NCT00115661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00115661 about?
NCT00115661 is a clinical study titled "Use of Rosiglitazone in the Treatment of Endometriosis". The purpose of this study is to perform a pilot study on the efficacy of rosiglitazone in reducing pelvic pain in early stage endometriosis patients.
What is the current status of trial NCT00115661?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2005-07. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00115661?
The interventions under investigation include: Rosiglitazone (DRUG).
Who is sponsoring clinical trial NCT00115661?
This trial is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.